title: Selection of a screening panel of rhinoviral serotypes.
abstract: A novel methodology for the selection of a representative primary and secondary screening panel of rhinoviral serotypes for the purposes of identifying potential antiviral agents is presented. This methodology focuses on the active-sites of the rhinoviral proteins but does not invoke historical SAR data, thereby avoiding compound bias.
authors.affiliation: AstraZeneca R&D Alderley Park, Cheshire SK10 4TF, UK. nick.tomkinson@astrazeneca.com
authors.forename: Nick
authors.initials: N
authors.lastname: Tomkinson
authors.forename: Mark
authors.initials: M
authors.lastname: Wenlock
authors.forename: Christopher
authors.initials: C
authors.lastname: McCrae
mesh_terms: D000998:Antiviral Agents / Q000494:pharmacology*; D057166:High-Throughput Screening Assays; D008958:Models, Molecular; D012229:Rhinovirus / Q000187:drug effects* / Q000276:immunology; D013329:Structure-Activity Relationship
chemical_list: D000998:Antiviral Agents